ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors

Application based on results from DESTINY-PanTumor02 trial and supported by additional ENHERTU data



Submission to be reviewed under FDA Real Time Oncology Review and Project Orbis



If approved,...

Related Keywords

United States ,Japan ,America ,American ,Daiichi Sankyo ,Ken Takeshita ,Susan Galbraith ,European Society For Medical Oncology ,Drug Administration ,Merck Co Inc ,Nasdaq ,Astrazeneca ,American Society Of Clinical Oncology ,Clinical Development Program ,Daiichi Sankyo Inc ,National Cancer Institute ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Breakthrough Therapy Designation ,Real Time Oncology Review ,Project Orbis ,Global Head ,Executive Vice President ,Medical Oncology ,New England Journal ,Clinical Oncology ,Lung Disease ,Breast Cancer ,Metastatic Gastric Cancer ,Absolute Neutrophil Count ,Positive Metastatic Breast ,Low Metastatic Breast ,Reproductive Potential ,Hepatic Impairment ,Prescribing Information ,Accessed January ,Enhertu Marks First Targeted Therapy ,Mutant Lung ,Markets ,